Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Sage_Therapeutics
|
| gptkbp:activities |
GABA receptor modulation
|
| gptkbp:brand |
brexanolone
|
| gptkbp:clinical_trial |
Phase 3
short-term treatment published in medical journals Study 201 Study 202 Study 203 |
| gptkbp:contraindication |
hypersensitivity to brexanolone
|
| gptkbp:dissolved |
water-soluble
|
| gptkbp:dosage_form |
gptkb:software_framework
|
| gptkbp:duration |
60 hours
continuous infusion |
| gptkbp:education |
important for understanding treatment
|
| gptkbp:effective_date |
March 19, 2019
|
| gptkbp:feedback |
generally positive
|
| gptkbp:frequency |
once per treatment cycle
|
| gptkbp:healthcare |
first drug specifically for postpartum depression
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zulresso
|
| gptkbp:ingredients |
brexanolone
|
| gptkbp:interacts_with |
CNS depressants
|
| gptkbp:is_monitored_by |
required during infusion
|
| gptkbp:is_used_for |
postpartum depression
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Sage_Therapeutics
|
| gptkbp:market |
gptkb:stock_market_index
|
| gptkbp:marketing_strategy |
ongoing
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:population |
women with postpartum depression
|
| gptkbp:price |
approximately $34,000 for treatment
|
| gptkbp:provides_information_on |
considered for severe cases
hospital or healthcare facility included in postpartum depression management |
| gptkbp:receives_funding_from |
supported by NIH
|
| gptkbp:requires |
available online
|
| gptkbp:research |
ongoing efficacy studies
|
| gptkbp:safety_features |
monitor for excessive sedation
|
| gptkbp:scholarships |
available through manufacturer
|
| gptkbp:side_effect |
anxiety
dizziness headache nausea vomiting insomnia sedation infusion site reactions |
| gptkbp:social_structure |
C21 H30 O5 S
|
| gptkbp:storage |
refrigerated
|
| gptkbp:student_enrollment |
adults only
|
| gptkbp:supports |
granted by FDA
|
| gptkbp:training |
recommended for administration
|
| gptkbp:treatment |
shown in clinical trials
enhances GAB Aergic transmission reduction in depression symptoms |
| gptkbp:type_of_insurance |
varies by plan
|